Level 2mixedASCO Annual Meeting 2026
Choueiri, Toni K. · Abstract 4502 · KEYNOTE-564 · 994 randomized (496 pembrolizumab, 498 placebo); baseline ctDNA in 736; cycle 5 day 1 ctDNA in 641
Natera Signatera RUO tissue-exome-based 16-plex and 64-plex assays
Baseline ctDNA was detectable in only 5.4% (16-plex) and 8.2% (64-plex) of 736 analyzed patients. ctDNA positivity was associated with worse DFS in both arms (P<0.05 for both assays), but sensitivity to predict DFS events was low and specificity was high. Among patients detectable at baseline and evaluable at cycle 5 day 1, clearance occurred in 6/10 vs 3/14 (16-plex) and 10/18 vs 9/25 (64-plex) with pembrolizumab vs placebo. The abstract concludes these data highlight limitations of these assays in clear-cell RCC.
Abstract
Level 3prognosticASCO Genitourinary Cancers Symposium 2026
Amaral, Paulo Siqueira do · Abstract 516 · 22 patients, 42 plasma samples; single-center retrospective
Next Personal Dx whole-genome tumor-informed assay (Personalis)
At a median follow-up of 7.0 months, 3 of 22 patients (14%) were ctDNA-positive at any timepoint (all <100 ppm); 2 of those 3 developed radiographic recurrence. Only 1 of 20 patients negative at the 3-month landmark recurred, and 0 of 16 with persistent ctDNA negativity recurred during follow-up.
Abstract
Level 2positiveASCO Genitourinary Cancers Symposium 2026, Abstract 537 2026
Tang C · Abstract 537 · NCT03575611 · 112 patients with KIM-1 measurements; median baseline KIM-1 127.0 pg/mL (IQR 71.5–228.0)
Personalized ctDNA detection panels (≤2000 somatic variants) from tumor whole-genome sequencing (Myriad Genetics); plasma KIM-1
ASCO GU 2026 abstract 537: among 112 patients, baseline and 3-month KIM-1 and ctDNA MRD were each associated with STFS in univariable and multivariable analyses; K-COMPASS (baseline KIM-1, baseline ctDNA MRD, and four clinical variables) had C-index 0.76 and calibration slope 1.
Abstract
Level 2positiveAACR Annual Meeting 2025, Abstract CT132 2025
Tang C · Abstract CT132 · NCT03575611 · 121 patients enrolled July 2018–May 2023 (NCT03575611)
Individualized ctDNA panels (Myriad Genetics) from tumor whole-genome sequencing; MRD+ if ctDNA detected
AACR 2025 abstract CT132 of NCT03575611: median PFS 18 months and median STFS 34 months in 121 patients; baseline ctDNA MRD+ in 56%, with shorter STFS (HR 2.9, 27 vs 54 months); 31% of baseline-MRD+ patients converted to MRD– at 3 months, and 3-month MRD+ was associated with shorter STFS (HR 4.3).
Abstract
Level 2positiveThe Oncologist, 2025, abstract 7 2025
Tang C · Abstract 7 · NCT03575611 · 121 patients (NCT03575611)
Individualized ctDNA panels (Myriad Genetics) from tumor whole-genome sequencing
The Oncologist abstract 7 reports the same NCT03575611 ctDNA analysis as AACR CT132, with baseline MRD+ in 56% (STFS HR 2.9, 27 vs 54 months) and 3-month MRD+ STFS HR 4.3; a few clinical tallies differ slightly from CT132 and are not pooled.
Abstract
Level 3neutralASCO Annual Meeting 2024, Abstract 3039 2024
Seo A · Abstract 3039 · 5 patients; 13 primary-tumor, 24 metastatic-lesion, and matched buffy-coat samples; baseline plasma before radiotherapy
Myriad Genetics High-Definition MRD assay: tumor/normal WGS (median coverage 30x); a sub-panel of up to 1,000 somatic variants designed for each lesion subsite; hybridization capture from plasma cfDNA
ASCO 2024 methods abstract (Seo first, Tang last): in 5 oligometastatic ccRCC patients, baseline MRD calls from Myriad High-Definition MRD sub-panels designed from primary-tumor vs metastatic subsites were fully concordant in 3 of 5 patients, at tumor fractions from 0.0004% to 0.027%.
Abstract
Level 3prognosticASCO Genitourinary Cancers Symposium 2023
Basu, Arnab · Abstract 715 · 41 patients with advanced RCC
Signatera (tumor-informed)
ctDNA was detected at any time point in 70% (29/41). All 14 patients who progressed had ctDNA detected ahead of radiographic progression (100% sensitivity in this series) with a median lead time of 13.6 weeks (range 1-39.7). Concordance between clinical outcome and ctDNA status was 78% (32/41).
AbstractFull paper